SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global single photon emission computed tomography market faces several challenges. There is strong competition from alternative neuroimaging modalities like MRI and CT scans that provide higher resolution images. The use of radiotracers also raises regulatory compliance issues. SPECT scans have lower sensitivity and need longer scanning times compared to PET. The high equipment and operational costs pose significant barriers, especially in price-sensitive developing markets.

Market Opportunities - Emerging Theragnostics applications of SPECT

Emerging theragnostic applications of SPECT could provide a significant opportunity for growth of global single photon emission computed tomography (SPECT) market. Theragnostics involves combining targeted cancer therapeutics with diagnostic imaging techniques. With SPECT's ability to provide molecular imaging data, it is uniquely positioned to advance theragnostic applications and personalize treatment plans for patients. SPECT can monitor drug delivery and response in real-time, evaluating aspects like bio distribution, pharmacokinetics and target engagement of novel radiolabeled therapeutics. For example, SPECT tracers are being studied alongside immune cell therapies to track immune cells after infusion and predict likelihood of response. By assessing the distribution and movement of cell therapies or targeted drugs throughout the body at a molecular level, SPECT can guide therapy adjustments on an individual basis. This precision approach aims to maximize outcomes while minimizing toxicity - an important goal given rising drug costs.